Pacific Edge seeks $35m as sales start to flow
Biotech minnow posts $10.7m loss as resources poured into US market.
Cancer diagnostics company Pacific Edge [NZX: PEB] is asking shareholders to tip in $35 million to fund its US growth strategy and explore opportunities in Asia.
After reporting $1.9m of sales and a $10.7m loss for the year to March, the company announced a fully underwritten renounceable rights
Want to read more? It's easy.
Choose your best value subscription option
Individual
Group membership
NBR Marketplace
Yearly Premium Online Subscription
NZ$499.00 / yearly
Monthly Premium Online Subscription
NZ$44.95 / monthly
Smartphone Only Subscription
NZ$24.95 / monthly
Premium Group Membership 10 Users
NZ$350+GST / monthly
$35 per user - Pay by monthly credit card debitPremium Group Membership 20 Users
NZ$600+GST / monthly
$30 per user - Pay by monthly credit card debitPremium Group Membership 50 Users
NZ$1250+GST / monthly
$25 per user - Pay by monthly credit card debitPremium Group Membership 100 Users
NZ$1875+GST / monthly
$18.75 per user - Pay by monthly credit card debitYearly Premium Online Subscription + NBR Marketplace
NZ$499.00 / yearly
Already have an account? Login
Tim Hunter
Thu, 28 May 2015
Thu, 28 May 2015
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Pacific Edge seeks $35m as sales start to flow
48108